Detalles de la búsqueda
1.
Health-related quality of life in patients with relapsed/refractory multiple myeloma treated with pomalidomide and dexamethasone ± subcutaneous daratumumab: Patient-reported outcomes from the APOLLO trial.
Am J Hematol
; 97(4): 481-490, 2022 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-35089607
2.
Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial.
Lancet Oncol
; 22(6): 801-812, 2021 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-34087126
3.
Subcutaneous daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (APOLLO): extended follow up of an open-label, randomised, multicentre, phase 3 trial.
Lancet Haematol
; 10(10): e813-e824, 2023 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-37793772
4.
Effects of altered cellular ultrastructure on energy metabolism in diabetic cardiomyopathy: an in silico study.
Philos Trans R Soc Lond B Biol Sci
; 377(1864): 20210323, 2022 11 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-36189807
5.
Biomechanical testing and material characterization for the rat large intestine: regional dependence of material parameters.
Physiol Meas
; 32(12): 1969-82, 2011 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-22056976
Resultados
1 -
5
de 5
1
Próxima >
>>